The Hematology/Oncology Pharmacy Association (HOPA) remains committed to fostering belonging within oncology pharmacy. We celebrate and support all pharmacy professionals dedicated to advancing cancer care and believe every person—regardless of background, identity, or circumstances—deserves access to the highest quality treatment.

Broad and varying perspectives and experiences strengthen our profession and enhance patient outcomes. By nurturing an inclusive environment, HOPA continues to advocate for equitable access to expert oncology pharmacy services for all.

Our commitment to this remains unwavering.

The Board of Directors has heard your concerns about the impact of recent Executive Orders. We recognize that many of our members work in government and other organizations where these policies directly affect your roles, while others seek clarity on how the patients you serve may be impacted.

HOPA will continue to monitor policy changes and regulations closely, with the goal of ensuring we support our members and the patients you serve to the best of our abilities.

Leadership medical image
Membership HOPA News

A Journey of a Thousand Miles Begins with a Single Step Navigating the Path to a Leadership Position

In this personal reflection from the latest issue of HOPA News, Mary Walters, PharmD, BCOP, and Peter Stuessy, PharmD, BCOP, compare and contrast their journeys into leadership roles - and what advice they would give others on their own leadership paths.

Young man in a pharmacist coat at work
Advocacy Membership

The Role of the IDS Pharmacy Technician

Members of the HOPA Investigational Drug Services (IDS) special interest group (SIG) have identified specific responsibilities and duties that differentiate the IDS technician role from other advanced and specialized technician roles.

Cancer pill medication
Advocacy Membership

HOPA and Coalition to Improve Access to Cancer Care Commend Reintroduction of Cancer Drug Parity Act

HOPA, along with the CIACC, recently voiced its support for the reintroduced Cancer Drug Parity Act, aiming to make oral and self-administered cancer treatments less expensive and more accessible.